|Day Low/High||74.05 / 75.41|
|52 Wk Low/High||65.47 / 99.14|
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Valeant is selling its Australian unit iNova to raise $930 million to pay down debt.
Stocks significantly pared losses by the end of the session, though still ended slightly lower.
The quarter's success, Canaccord Genuity analyst Dewey Steadman argued, means Perrigo has removed an overhang.
Core CPI has slowed on a year-over-year basis now for three consecutive months.
The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
David Einhorn is going all-in on General Motors.
New Directors Nominated by Starboard in Accordance With Previously Announced Agreement
Doug Kass shares his thoughts on Facebook, Allergan and Apple.
Stocks hold mostly lower on Wednesday after the Federal Reserve's policy-making group decides to leave its federal funds rate unchanged.
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
Goldberg Law PC announces that it is investigating Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) concerning possible violations of federal securities laws.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Perrigo Co.
The search involves a Department of Justice Antitrust Division investigation in relation to drug pricing in the pharmaceutical industry
Stock losses deepen on Wednesday morning after crude oil turns negative and a decision from the Federal Reserve looms.
The investigation is in relation to drug pricing in the pharmaceutical industry.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
- Tysabri® historical royalty stream determined to be a financial asset; Company to file 2016 Form 10-K, including restated fiscal 2014, fiscal 2015 and transition period 2015 audited financials and certain quarterly financial information as soon as practical